ArticleBMC infectious diseases2026
Schistosoma mansoni co-infection in tuberculosis patients with or without human immunodeficiency virus and factors associated with treatment outcomes: a prospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical outcomes associated with schistosome infection and alcohol use: A systematic scoping review.PLoS neglected tropical diseases · 2026Article
- Associations of Schistosoma mansoni Infection, Latent Tuberculosis, Host Interferon-γ Concentrations, and Praziquantel Treatment in Tanzanian Adults.The American journal of tropical medicine and hygiene · 2026Article
Corrections and comments
- Update of
Authors and funding
20 authors.
Funding
Abstract
backgroundTuberculosis (TB) has resurfaced as the leading cause of death by an infectious agent after the COVID-19 pandemic. The fight against TB needs to consider factors associated with mycobacterial reactivation and treatment of TB disease. Recent findings showed that Schistosoma mansoni co-infection leads to a Th2/Th1 profile that results in an immune modulation that favors the escape of the Mycobacteria. Schistosoma mansoni may contribute to tuberculosis (TB) incidence in endemic regions. We aimed to determine the co-infection rate and treatment outcomes.
methodsA prospective cohort study was conducted between 2020 and 2022 at the University Clinical Research Center (UCRC). We included culture-confirmed pulmonary TB patients who were tested for Schistosoma mansoni in stools using Kato-Katz. S. mansoni co-infection was determined at baseline. Patients were classified into two -groups: TB/S. mansoni co-infected and TB-mono-infected. Univariable and multivariable logistic regression were performed to identify factors associated with the co-infection.
resultsWe analyzed data from 174 tuberculosis-confirmed patients tested with Kato-Katz technique. Schistosoma mansoni co-infection among TB patients was 28.7%. The death rate was 18.0% in the co-infection group versus 5.6% in TB-mono-infected. Death was associated with bilateral lung opacities [aOR = 4.29 (2.98–18.74), p = 0.038]. TB/S. mansoni co-infection represented a high risk of death [aOR = 4.31 (1.17–15.90), p = 0.029]. However, HIV infection was not associated with death [aOR = 1.29 (0.18–9.20), p = 0.799].
conclusionsSchistosoma mansoni co-infection was found in one-third of active TB patients, 2.5-fold higher than that of HIV. The co-infection was associated with death, and bilateral lung opacities were associated with a higher risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.